Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22965358 | 0.87 | CARM1 (0.45) | HRH3CYP2C9CYP3A4CARM1PRMT6 | |
| SCHEMBL18592218 | 0.86 | DRD2 (0.40) | HRH3CYP2C9KCNH2CYP3A4CARM1 | |
| SCHEMBL21965867 | 0.82 | DRD2 (0.46) | DRD2SLC18A3 | |
| SCHEMBL23664607 | 0.81 | NCF1 (0.40) | HRH3DRD2HRH1 | |
| SCHEMBL18591774 | 0.80 | PRCP (0.42) | CARM1PRMT6DRD2SLC18A3 | |
| SCHEMBL25053674 | 0.75 | DRD2 (0.44) | HRH3CYP2C9DRD2SLC18A3HRH1 | |
| SCHEMBL24654217 | 0.70 | LTA4H (0.38) | HRH3CYP2C9CYP3A4 | |
| SCHEMBL22692312 | 0.68 | SIGMAR1 (0.35) | HRH3KCNH2CARM1PRMT6HRH1 | |
| SCHEMBL18591747 | 0.67 | DRD4 (0.41) | HRH3DRD2HRH1SIGMAR1 | |
| SCHEMBL24673680 | 0.66 | DRD2 (0.43) | CYP3A4CARM1PRMT6DRD2SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | HRH3 3301/4885CYP2C9 4703/4885KCNH2 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.